A scalable, profitable remote care service line for Alaska Heart & Vascular Institute: remote monitoring and principal care management for heart failure and hypertension, sorted by Envoy attribution, billed under AHVI’s own NPIs, run by a CoachCare care team inside athenahealth, and live February 1, inside the first ASM performance year.
Three months ago this was a whole-panel estimate. It is now a deployment plan built on AHVI’s own census, Envoy’s own attribution report and the final 2027 fee schedule, with a go-live date. Each step below changed the plan.
AHVI pulled its Medicare census in three groups: heart failure only, hypertension only, and both. That gave us 17,049 patients, 5,038 with heart failure and 12,011 with hypertension and no heart failure. Every figure on this page starts there.
CoachCare’s leadership and clinical team worked through the Alaska questions in person: statewide device shipping and connectivity, the on-site enrollment specialist role, care management and escalation protocols, and the closed-loop athenahealth integration.
AHVI founded Envoy Integrated Health ACO, so a care-management dollar spent on an attributed patient also lands in Envoy’s benchmark. We checked Envoy’s financial and quality results against CMS’s public files, then split the panel into three lanes by who carries the economics.
Envoy’s August 2026 report attributes 809 AHVI patients, 4.7% of the 17,049. That replaced our placeholder and shrank the ACO question to a small post-discharge slice.
Exclude them entirely, enroll them only after a heart failure discharge, or enroll every heart failure patient with no screen. This plan uses the second option. The first stays available as a fallback.
The week CMS finalized the 2027 fee schedule, we built a dated go-live plan for the first ASM performance year. It is section 03 below, now set for February 1 to leave room for onboarding around the holidays.
CMS finalized the 2027 Physician Fee Schedule in November. It keeps remote monitoring open, holds the rates for the clinical work and adds one guardrail at enrollment. Every figure on this page is at the final 2027 rates for Anchorage.
| Code | Service | 2026 | 2027 final |
|---|---|---|---|
| 99453 | RPM setup and education | $22.78 | $20.70 |
| 99445 | RPM device supply, 2–15 days | $55.32 | $42.95 |
| 99454 | RPM device supply, 16–30 days | $55.32 | $42.95 |
| 99470 | RPM management, first 10 min | $31.91 | $31.93 |
| 99457 | RPM management, first 20 min | $63.31 | $62.53 |
| 99458 | RPM management, each extra 20 min | $52.29 | $51.58 |
| 99426 | PCM, first 30 min | $85.54 | $83.31 |
| 99427 | PCM, each extra 30 min | $67.08 | $66.05 |
| 99495 | TCM, moderate complexity | $271.55 | $260.75 |
| 99496 | TCM, high complexity | $368.96 | $355.16 |
Readings reviewed by CoachCare nurses, with monthly care management around them. CMS kept RPM for these patients, and advanced heart failure (NYHA III–IV) is excluded from ACCESS, so AHVI’s ASM cohort stays on RPM.
CMS’s voluntary ACCESS model pays about $420 a year per patient on its cardio-kidney-metabolic track, part of it tied to outcomes. In the first quarter of 2027 we review which AHVI hypertension patients fit ACCESS better than RPM and decide together whether to apply.
Five stages to a February 1 go-live, with the holiday weeks kept light so onboarding never competes with year-end. CoachCare runs the build inside athenahealth. AHVI’s cardiologists make every clinical call.
CMS’s final participant list, posted September 17, puts ten AHVI cardiologists in the Ambulatory Specialty Model’s heart failure cohort, on a historical Part B base of about $4.65M. Performance in 2027 sets a two-sided payment adjustment in 2029, and the range widens every year after. The monitoring, post-discharge follow-up and longitudinal management in this plan are the work ASM measures.
ASM adjusts covered professional Part B payments broadly, not only remote care claims. That is why the exposure base is $4.65M rather than the program’s own billing.
Fewer inpatient and emergency events from the two heart failure lanes, at a 60% ASM-managed share of the census. A direction, not a predicted CMS score.
Only the 2029 payment (~$189K) falls inside the 36-month window. At a zero score the first-year downside is $444K, which is the case for having the workflow live early in the year.
For a patient outside any ACO benchmark, every dollar of RPM and PCM margin is AHVI’s to keep. For a patient Envoy is accountable for, the same dollar also raises Envoy’s benchmark, and the program has to avoid enough admissions to pay that back. AHVI is a specialty practice, so patients attribute to their primary care physicians and the attributed slice is small. The non-attributed lanes carry the deployment.
Envoy assigns retrospectively, so the working filter is the referring primary care physician: the six Envoy primary care TINs. Roughly one patient in twenty sits inside the benchmark.
Non-attributed heart failure and hypertension patients bill RPM and PCM with no ACO exposure. These two lanes run at full enrollment-specialist capacity from month one.
A post-discharge heart failure cohort avoids enough admissions to outrun the care-management spend it adds to Envoy’s benchmark. Attributed patients enter through a qualifying discharge, not a panel sweep.
Two dedicated enrollment specialists, hired in Anchorage and paid by CoachCare, each with capacity for about 80 enrollments a month. One runs heart failure and staffs the post-discharge window first. The other runs hypertension.
Lane B, about 4 a month. The post-discharge window is short, so these patients are staffed first.
Lane A, the rest. Non-attributed heart failure takes the remaining capacity until it reaches its 1,680 ceiling in month 27, then drops to replacement enrollment.
Against a 11,440-patient pool and a 3,432 ceiling, 80 a month less attrition reaches about 2,238 active patients by month 36. Enrollment capacity, not the population, is the limit on this lane.
A 36-month forecast of the three lanes on AHVI’s census at Anchorage Medicare rates, launching February 2027, inside the first ASM performance year. Contribution margin is what AHVI keeps.
| Lane | Year 1 | Year 2 | Year 3 | 36-Month |
|---|---|---|---|---|
| Lane A · non-attributed HF | $551,045 | $1,431,419 | $1,931,278 | $3,913,742 |
| Lane B · attributed HF | $28,081 | $49,113 | $49,192 | $126,386 |
| Lane C · non-attributed HTN | $473,586 | $1,231,427 | $1,863,567 | $3,568,580 |
| Contribution margin, all lanes | $1,052,712 | $2,711,959 | $3,844,037 | $7,608,708 |
Cost scales with the patients on program, so there is no payback period to finance and no month in which cumulative contribution margin is negative.
Referring providers set the referral supply. The starting 25 providers supply about 160 a month, which is the two specialists’ capacity, so fewer providers or another specialist makes referrals the limit. The starting 12-month ramp is slower than the forecast above, which runs at full pace from month one. Penetration and enrollment rate set each lane’s ceiling; the specialists set how fast the lane climbs toward it.
Across the two heart failure lanes over 36 months, at a 40% reduction on a 40% annual admission rate. Lane C claims margin only.
The attributed post-discharge cohort alone, with about 12 emergency visits avoided beside them.
Over 36 months, beside 140 post-discharge enrollments in Lane B and 2,880 in Lane C.
Monthly for all three lanes from a February 2027 go-live, at final 2027 rates throughout.
Every Lane B care-management dollar raises Envoy’s benchmark. Enrolling after a discharge lets avoided admissions and emergency visits outweigh that spend, so Envoy’s total cost of care improves while AHVI still earns margin on the lane.
0.12 points of Envoy’s benchmark, against a 1.5-point budget.
From admissions and emergency visits avoided on a ~42-patient census.
The lane needs 13.2 avoided admissions per 100 patient-years to break even; the modeled cohort delivers 20.
| PCM share on Lane B | 0% | 25% | 50% | 70% · modeled | 100% |
|---|---|---|---|---|---|
| Added to Envoy’s benchmark | 0.08 pts | 0.09 pts | 0.11 pts | 0.12 pts | 0.14 pts |
| Net benefit to Envoy | +$85K/yr | +$74K/yr | +$62K/yr | +$52K/yr | +$38K/yr |
| Avoided admissions per 100 needed to break even | 8.3 of 20 | 10.0 of 20 | 11.8 of 20 | 13.2 of 20 | 15.3 of 20 |
| AHVI contribution margin, Lane B | $29K/yr | $36K/yr | $43K/yr | $49K/yr | $58K/yr |
In Alaska a remote care program fails at the seams: a ten-day transit to a village post office, a community without LTE, an EHR migration in flight. One partner has to carry the whole set.
Platform, cellular devices and SIMs, device logistics, a US-based W-2 care team, billing and analytics, all run by CoachCare. Devices arrive configured and transmit over cellular with no smartphone, app or home internet, which is what makes the program statewide.
60+ ambulatory cardiology sites, including Cardiac Solutions, Western Washington Medical Group, MercyOne Iowa Heart and AMS Cardiology. Cardiology protocols, a five-rung escalation ladder and a fixed three-touch post-discharge sequence AHVI signs before go-live.
Eligibility flags surface candidates in the chart, readings and care-plan time write back, and claims generate into athenahealth. athenaPractice and athenaOne are both supported.
A named care team staffed to AHVI and trained on AHVI’s protocols, at a 160:1 ratio rather than the 300:1 common in the market. Only two things come back to an AHVI clinician: the exceptions, and the claim.
Symptom and vitals trends surface progression in monitored aortic stenosis patients. Post-discharge weight and pressure are tracked after CABG and PCI. Device-captured blood pressure over time is the evidence a renal denervation referral needs.
A 29.1 mmHg average drop in Stage 2 hypertension across 2,738 patients at Cardiac Solutions (case study). Zero 30-day readmissions across six months among 450 advanced heart failure patients at Iowa Heart (case study). 74% fewer admissions in six months at Advocate Aurora (case study).